223Ra

You have access
Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
Michael C. Bellavia, Ravi B. Patel and Carolyn J. Anderson

Journal of Nuclear Medicine November 1, 2022, 63 (11) 1636-1641; DOI: https://doi.org/10.2967/jnumed.122.264373
You have access
²²³Ra Induces Transient Functional Bone Marrow Toxicity
Maria Parlani, Francesco Boccalatte, Anna Yeaton, Feng Wang, Jianhua Zhang, Iannis Aifantis and Eleonora Dondossola

Journal of Nuclear Medicine October 1, 2022, 63 (10) 1544-1550; DOI: https://doi.org/10.2967/jnumed.121.263310
You have access
Enhancing ²²³Ra Treatment Efficacy by Anti-β1 Integrin Targeting
Claudia Paindelli, Stefano Casarin, Feng Wang, Luis Diaz-Gomez, Jianhua Zhang, Antonios G. Mikos, Christopher J. Logothetis, Peter Friedl and Eleonora Dondossola

Journal of Nuclear Medicine July 1, 2022, 63 (7) 1039-1045; DOI: https://doi.org/10.2967/jnumed.121.262743
Open Access
¹⁷⁷Lu-Prostate-Specific Membrane Antigen Ligand After ²²³Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
Oliver Sartor, Christian la Fougère, Markus Essler, Samer Ezziddin, Gero Kramer, Jörg Ellinger, Luke Nordquist, John Sylvester, Giovanni Paganelli, Avivit Peer, Martin Bögemann, Jeffrey Meltzer, Per Sandström, Frank Verholen and Daniel Y. Song

Journal of Nuclear Medicine March 1, 2022, 63 (3) 410-414; DOI: https://doi.org/10.2967/jnumed.121.262240
Open Access
Improved ²²³Ra Therapy with Combination Epithelial Sodium Channel Blockade
Diane S. Abou, Amanda Fears, Lucy Summer, Mark Longtine, Nadia Benabdallah, Ryan C. Riddle, David Ulmert, Jeff M. Michalski, Richard L. Wahl, Denise Chesner, Michele Doucet, Nicholas C. Zachos, Brian W. Simons and Daniel L.J. Thorek

Journal of Nuclear Medicine December 1, 2021, 62 (12) 1751-1758; DOI: https://doi.org/10.2967/jnumed.121.261977
You have access
The Prognostic Value of Quantitative Bone SPECT/CT Before ²²³Ra Treatment in Metastatic Castration-Resistant Prostate Cancer
Helmut Dittmann, Sabine Kaltenbach, Matthias Weissinger, Francesco Fiz, Peter Martus, Maren Pritzkow, Juergen Kupferschlaeger and Christian la Fougère

Journal of Nuclear Medicine January 1, 2021, 62 (1) 48-54; DOI: https://doi.org/10.2967/jnumed.119.240408
You have access
Assessing Radiographic Response to ²²³Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients
Aseem Anand, Elin Trägårdh, Lars Edenbrandt, Lars Beckman, Jan-Henry Svensson, Camilla Thellenberg, Anders Widmark, Jon Kindblom, Anders Ullén and Anders Bjartell

Journal of Nuclear Medicine May 1, 2020, 61 (5) 671-675; DOI: https://doi.org/10.2967/jnumed.119.231100
You have access
Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with ²²³Ra: The Role of Bystander Effects and Their Potential for Therapy
Calvin N. Leung, Brian S. Canter, Didier Rajon, Tom A. Bäck, J. Christopher Fritton, Edouard I. Azzam and Roger W. Howell

Journal of Nuclear Medicine January 1, 2020, 61 (1) 89-95; DOI: https://doi.org/10.2967/jnumed.119.227835
You have access
²²³Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity
Marie Øbro Fosbøl, Peter Meidahl Petersen, Andreas Kjaer and Jann Mortensen

Journal of Nuclear Medicine April 1, 2018, 59 (4) 596-602; DOI: https://doi.org/10.2967/jnumed.117.195677
You have access
⁶⁸Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with ²²³Ra: Proof of Concept
Hojjat Ahmadzadehfar, Kambiz Azgomi, Stefan Hauser, Xiao Wei, Anna Yordanova, Florian C. Gaertner, Stefan Kürpig, Holger Strunk and Markus Essler

Journal of Nuclear Medicine March 1, 2017, 58 (3) 438-444; DOI: https://doi.org/10.2967/jnumed.116.178533

Main menu

User menu

Search

223Ra

Pages